Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvalYear |
2014
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XC19
|
| gptkbp:brand |
gptkb:Blincyto
|
| gptkbp:CASNumber |
1353555-47-9
|
| gptkbp:developedBy |
gptkb:Amgen
|
| gptkbp:drugClass |
antineoplastic agent
|
| https://www.w3.org/2000/01/rdf-schema#label |
blinatumomab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
bispecific T-cell engager
|
| gptkbp:molecularWeight |
54800 Da
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
cytokine release syndrome
neurological toxicity |
| gptkbp:target |
gptkb:CD3
gptkb:CD19 |
| gptkbp:UNII |
Q1P0P0JZ5N
|
| gptkbp:usedFor |
gptkb:relapsed/refractory_B-cell_precursor_ALL
leukemia |
| gptkbp:bfsParent |
gptkb:CD19
|
| gptkbp:bfsLayer |
6
|